Compare iShares 20 Plus Year Treasury Bond ETF (TLT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 20 Plus Year Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 20 Plus Year Treasury Bond ETF trades at $77.85 (market cap $47.61B), while State Street SPDR S&P Biotech ETF trades at $154.35 (market cap $10.11B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 4.7× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 20 Plus Year Treasury Bond ETF for 83 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| TLT | XBI | |
|---|---|---|
Market Cap | $47.61B | $10.11B |
Volume | 49,263,490 | 12,903,266 |
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $92.06 | $169.55 |
52-Week Low | $77.11 | $104.99 |
Typical Hold Time | 83 Days | 37 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.71 with a slight 0.73% daily gain amid a challenging bond market environment. The technical picture remains bearish with moving averages signaling continued pressure, while oscillators show neutral momentum. Recent news highlights Treasury yields reaching multi-decade highs, with the fund down 11% year-to-date and 46% over five years as investors face a new era of higher interest rates.
The outlook for TLT remains pressured by rising interest rates and inflation concerns, though current yields near 5.3% offer attractive income potential. Key risks include further Fed tightening and economic uncertainty, while potential catalysts could emerge from any moderation in inflation or economic slowdown that might prompt rate cuts.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
